Skip to Content

Fungizone For Tissue Culture Side Effects

Generic Name: amphotericin b

Note: This document contains side effect information about amphotericin b. Some of the dosage forms listed on this page may not apply to the brand name Fungizone For Tissue Culture.

For the Consumer

Applies to amphotericin b: injectable, powder for solution

Along with its needed effects, amphotericin b (the active ingredient contained in Fungizone For Tissue Culture) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking amphotericin b:

More commonWith intravenous injection
  • Fever and chills
  • headache
  • increased or decreased urination
  • irregular heartbeat
  • muscle cramps or pain
  • nausea
  • pain at the place of injection
  • unusual tiredness or weakness
  • vomiting
Less common or rareWith intravenous injection
  • Blurred or double vision
  • convulsions (seizures)
  • numbness, tingling, pain, or weakness in hands or feet
  • shortness of breath, troubled breathing, wheezing, or tightness in chest
  • skin rash or itching
  • sore throat and fever
  • unusual bleeding or bruising
With spinal injection
  • Blurred vision or any change in vision
  • difficult urination
  • numbness, tingling, pain, or weakness

Some side effects of amphotericin b may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More commonWith intravenous injection
  • Diarrhea
  • headache
  • indigestion
  • loss of appetite
  • nausea or vomiting
  • stomach pain
Less commonWith spinal injection
  • Back, leg, or neck pain
  • dizziness or lightheadedness
  • headache
  • nausea or vomiting

For Healthcare Professionals

Applies to amphotericin b: compounding powder, compounding powder for reconstitution, intravenous powder for injection, oral suspension

General

Oral amphotericin B is not appreciably absorbed, even at high dosage, and systemic adverse effects have not been noted.

Intravenous amphotericin B will lead to some intolerance in most patients, even at less than the full therapeutic dose. Tolerance can be improved by treatment with antipyretics, antihistamines, or antiemetics. Meperidine may decrease the duration of chills and fever that accompany infusion. Small doses of IV adrenal corticosteroids just prior to or during infusion may decrease febrile reactions. Heparin and use of a pediatric scalp-vein needle may lessen thrombophlebitis incidence.[Ref]

Renal

Very common (10% or more): Renal function test abnormalities (including azotemia, hyposthenuria, renal tubular acidosis, and nephrocalcinosis), blood creatinine increased
Common (1% to 10%): Renal failure acute
Uncommon (0.1% to 1%): Renal impairment
Rare (less than 0.1%): Nephrogenic diabetes insipidus[Ref]

Renal function test abnormalities usually improve upon interruption of therapy, however some permanent impairment often occurs, especially in patients receiving large cumulative doses (over 5 grams). Concomitant diuretic use may predispose patient for renal impairment, whereas sodium repletion/supplementation may reduce nephrotoxicity occurrence.[Ref]

Metabolic

Very common (10% or more): Hypokalemia
Common (1% to 10%): Hypomagnesemia, decreased appetite
Rare (less than 0.1%): Hyperkalemia
Frequency not reported: Hypocalcemia[Ref]

Gastrointestinal

Common (1% to 10%): Mild gastrointestinal distress, nausea, vomiting, diarrhea
Uncommon (0.1% to 1%): Abdominal pain upper
Rare (less than 0.1%): Dyspepsia, hemorrhagic gastroenteritis, melena
Frequency not reported: Transient yellowing of the teeth (oral route), cramping, epigastric pain[Ref]

Hematologic

Common (1% to 10%): Anemia
Uncommon (0.1% to 1%): Agranulocytosis, leukopenia, thrombocytopenia
Rare (less than 0.1%): Coagulopathy, eosinophilia, leukocytosis
Frequency not reported: Normochromic normocytic anemia[Ref]

Nervous system

Common (1% to 10%): Headache
Uncommon (0.1% to 1%): Neuropathy peripheral
Rare (less than 0.1%): Encephalopathy, convulsion, tinnitus, vertigo[Ref]

Hypersensitivity

Very rare (less than 0.01%): Anaphylactoid/anaphylactic reactions[Ref]

Cardiovascular

Cardiovascular side effects have been reported rarely. These have included hypotension, tachypnea, cardiac arrest, shock, cardiac failure, pulmonary edema, arrhythmia, including ventricular fibrillation, dyspnea, hypertension, and transient asystole. Thrombophlebitis has occurred in many patients because of the long duration of intravenous therapy usually required.[Ref]

Musculoskeletal

Chills usually occur within 15 to 20 minutes after initiation of infusion[Ref]

Very common (10% or more): Chills
Uncommon (0.1% to 1%): Myalgia
Rare (less than 0.1%): Arthralgia[Ref]

Respiratory

Very common (10% or more): Dyspnea
Uncommon (0.1% to 1%): Bronchospasm
Frequency not reported: Tachypnea, wheezing, pulmonary edema, hypersensitivity pneumonitis[Ref]

Hepatic

Common (1% to 10%): Liver function test abnormalities, hepatic function abnormal
Uncommon (0.1% to 1%): Jaundice
Rare (less than 0.1%): Acute hepatic failure[Ref]

Other

Very common (10% or more): Pyrexia
Rare (less than 0.1%): Deafness, pain and malaise, weight decreased
Frequency not reported: Hearing loss[Ref]

Dermatologic

Common (1% to 10%): Rash
Rare (less than 0.1%): Urticaria, angioedema, rash maculopapular, pruritus, skin exfoliation, Stevens-Johnson syndrome, toxic epidermal necrolysis[Ref]

Local

Common (1% to 10%): Injection site pain (with or without phlebitis or thrombophlebitis)[Ref]

Ocular

Rare (less than 0.1%): Vision blurred, diplopia
Frequency not reported: Visual impairment[Ref]

Genitourinary

Rare (less than 0.1%): Anuria, oliguria[Ref]

References

1. Lyman C, Walsh T "Systemically administered antifungal agents." Drugs 44 (1992): 9-35

2. Gales MA, Gales BJ "Rapid infusion of amphotericin B in destrose." Ann Pharmacother 29 (1995): 523-9

3. Kan V, Bennett J, Amantea M, et al. "Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers." J Infect Dis 164 (1991): 418-21

4. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

5. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK "Injectable paromomycin for Visceral leishmaniasis in India." N Engl J Med 356 (2007): 2571-81

6. Griswold MW, Briceland LL, Stein DS "Is amphotericin B test dosing needed?" Ann Pharmacother 32 (1998): 475-7

7. Thompson GR 3rd, Cadena J, Patterson TF "Overview of antifungal agents." Clin Chest Med 30 (2009): 203-15, v

8. Nicholl TA, Nimmo CR, Shepherd JD, Phillips P, Jewesson PJ "Amphotericin B infusion-related toxicity: comparison of two- and four-hour infusions." Ann Pharmacother 29 (1995): 1081-7

9. Cerner Multum, Inc. "Australian Product Information." O 0

10. "Product Information. Amphotericin B (amphotericin B)." X-Gen Pharmaceuticals Inc, Big Flats, NY.

11. Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela TH "Pretreatment regimens for adverse events related to infusion of amphotericin B." Clin Infect Dis 20 (1995): 755-61

12. Cruz JM, Peacock JE, Loomer L, et al "Rapid intravenous infusion of amphotericin B: a pilot study." Am J Med 93 (1992): 123-30

13. Fisher MA, Talbot GH Maislin G, McKeon BP, Tynan KP, Strom BL "Risk factors for amphotericin B-associated nephrotoxicity." Am J Med 87 (1989): 547-52

14. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH "The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy." Am J Med 111 (2001): 528-34

15. Deray G "Amphotericin B nephrotoxicity." J Antimicrob Chemother 49 Suppl A (2002): 37-41

16. "Amphotericin." Med Lett Drugs Ther 30 (1988): 30-2

17. Shindo K, Mizuno T, Matsumoto Y, et al "Granulocytopenia and thrombocytopenia associated with combination therapy of amphotericin B and low-dose flucytosine in a patient with cryptococcal meningitis." DICP 23 (1989): 672-4

18. "Product Information. Fungizone (amphotericin B)." Bristol-Myers Squibb, Princeton, NJ.

19. Bullock W, Luke R, Nuttall C, Bhathena D "Can mannitol reduce amphotericin B nephrotoxicity?" Antimicrob Agents Chemother 10 (1976): 555-63

20. Eriksson U, Seifert B, Schaffner A "Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial." BMJ 322 (2001): 579-82

21. Clements J, Peacock J "Amphotericin B revisited: reassessment of toxicity." Am J Med 88 (1990): n22-7

22. Girmenia C, Gentile G, Micozzi A, Martino P "Nephrotoxicity of amphotericin B desoxycholate." Clin Infect Dis 33 (2001): 915-6

23. McCurdy D, Frederic M, Elkinton JR "Renal tubular acidosis due to amphotericin B." N Engl J Med 268 (1968): 124-31

24. Peleg AY, Woods ML "Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients." J Antimicrob Chemother 54 (2004): 803-8

25. Branch R, Jackson E, Jacqz E, et al "Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline." Klin Wochenschr 65 (1987): 500-6

26. Patterson R, Ackerman G "Renal tubular acidosis due to amphotericin B nephrotoxicity." Arch Intern Med 127 (1971): 241-4

27. Saag MS, Powderly WG, Cloud GA, et al "Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis." N Engl J Med 326 (1992): 83-9

28. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L, Bowden R, Anaissie E, Hiemenz J, Lister J "Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis." Clin Infect Dis 29 (1999): 1402-7

29. Fischer J, Dewald J "Parkinsonism associated with intraventricular amphotericin B." J Antimicrob Chemother 12 (1983): 97-9

30. Klibanov OM, Raasch RH, Rublein JC "Changes in renal function after changes in antifungal drug therapy." Am J Health Syst Pharm 61 (2004): 50-3

31. Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DRJ, Dasbach EJ, Platt R "Mortality and costs of acute renal failure associated with amphotericin B therapy." Clin Infect Dis 32 (2001): 686-93

32. Eriksson U, Seifert B, Schaffner A "Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial." Br Med J 322 (2001): 579-82

33. Cleary J, Weisdorf D, Fletcher C "Effect of infusion rate on amphotericin B-associated febrile reactions." Drug Intell Clin Pharm 22 (1988): 769-72

34. Sacks P, Fellner S "Recurrent reversible acute renal failure from amphotericin." Arch Intern Med 147 (1987): 593-5

35. Arning M, Scharf R, Schneider W "Prevention of renal failure during long-term treatment with amphotericin-B." Klin Wochenschr 65 (1987): 1108

36. Rosch J, Pazin G, Fireman P "Reduction of amphotericin B nephrotoxicity with mannitol." JAMA 235 (1976): 1995-6

37. Maddux M, Barriere S "A review of complications of amphotericin B therapy: recommendations for prevention and management." Drug Intell Clin Pharm 14 (1980): 177-81

38. Barton C, Pahl M, Vaziri N, Cesario T "Renal magnesium wasting associated with amphotericin B therapy." Am J Med 77 (1984): 471-4

39. Branch R "Prevention of amphotericin B-induced renal impairment: a review on the use of sodium supplementation." Arch Intern Med 148 (1988): 2389-94

40. Barlows TG, Luber AD, Jacobs RA, Guglielmo BJ "Hypothermia following the intravenous administration of amphotericin B." Clin Infect Dis 23 (1996): 1187-8

41. Marcus N, Garty BZ "Transient hypoparathyroidism due to amphotericin B-induced hypomagnesemia in a patient with beta-thalassemia." Ann Pharmacother 35 (2001): 1042-4

42. Miller R, Bates J "Amphotericin B toxicity." Ann Intern Med 71 (1969): 1089-95

43. Wazny LD, Brophy DF "Amiloride for the prevention of amphotericin B-induced hypokalemia and hypomagnesemia." Ann Pharmacother 34 (2000): 94-7

44. Miller M "Reversible hepatotoxicity related to amphotericin B." Can Med Assoc J 131 (1984): 1245-7

45. Saklayen M "CAPD peritonitis: incidence, pathogens, diagnosis, and management." Med Clin North Am 74 (1990): 997-1010

46. Roncoroni A, Corrado C, Besuschio S, Pavlovsky S, Narvaiz M "Bronchiolitis obliterans possibly associated with amphotericin B." J Infect Dis 161 (1990): 589

47. Chan CS, Tuazon CU, Lesin LS "Amphotericin-B-induced thrombocytopenia." Ann Intern Med 96 (1982): 332-3

48. Struijk D, Krediet R, Boeschoten E, Rietra JG, Arisz L "Antifungal treatment of candida peritonitis in continuous ambulatory peritoneal dialysis patients." Am J Kidney Dis 9 (1987): 66-70

49. Weddington W "Delirium and depression associated with amphotericin B." Psychosomatics 23 (1982): 1076-8

50. Kan V, Bennett J, Amantea M, et al "Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B desoxycholate in healthy male volunteers." J Infect Dis 164 (1991): 418-21

51. Li P, Lai K "Amphotericin B-induced ocular toxicity in cryptococcal meningitis." Br J Ophthalmol 73 (1989): 397-8

52. Ellis WG, Sobel RA, Nielsen LS "Leukoencephalopathy in patients treated with amphotericin B methylester." J Infect Dis 146 (1982): 125-37

53. Carnevale NT, Galgiani JN, Stevens DA, Herrick MK, Langston JW "Amphotericin B-induced myelopathy." Arch Intern Med 140 (1980): 1189-92

54. Aruna AS, Al-Samarrai SA, Al-Humaidan AS "Amphotericin B-induced seizures in a patient with AIDS." Ann Pharmacother 35 (2001): 1037-41

55. Giglioitti F, Shenep J, Lott L, Thornton D "Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B." J Infect Dis 156 (1987): 784-9

56. Heinemann C, Wiesend CL, Hipler C, Norgauer J, Ziemer M "Acute generalized exanthematous pustulosis (AGEP) after oral use of amphotericin B." J Am Acad Dermatol 57(2 Suppl) (2007): S61-3

57. Kounis GN, Kouni SA, Chiladakis JA, Kounis NG "Comment: Mesalamine-Associated Hypersensitivity Myocarditis in Ulcerative Colitis and the Kounis Syndrome (February)." Ann Pharmacother 43 (2009): 393-4

58. Dules CS, Perfect JR "Amphotericin B-induced malignant hypertensive episodes." J Infect Dis 161 (1990): 588

59. DeMonaco HJ, McGovern B "Transient asystole associated with amphotericin B infusion." Drug Intell Clin Pharm 17 (1983): 547-8

60. Craven P, Gremillion D "Risk factors of ventricular fibrillation during rapids amphotericin B infusion." Antimicrob Agents Chemother 27 (1985): 868-71

61. Katz BZ, Cohn RA "Amphotericin b and hypertension." Pediatr Infect Dis J 13 (1994): 839-40

62. Le Y, rana KZ, Dudley MN "Amphotericin B-associated hypertension." Ann Pharmacother 30 (1996): 765-7

63. Le Y, Rana KZ, Dudley MN "Amphotericin b-associated hypertension." Ann Pharmacother 30 (1996): 765-7

64. Levine S, Walsh T, Martinez A, Eichacker PA, Lopez-Berestein G, Natanson "Cardiopulmonary toxicity after liposomal amphotericin B infusion." Ann Intern Med 114 (1991): 664-6

65. Haber R, Oddone E, Gurbel P, Stead W "Acute pulmonary decompensation due to amphotericin B in the absence of granulocyte transfusions." N Engl J Med 215 (1986): 836

66. Krimerman SM, Potasman I, Barak A "Pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions." Crit Care Med 17 (1989): 1081

67. Gill J, Sprenger HR, Ralph ED, Sharpe MD "Hepatotoxicity possibly caused by amphotericin B." Ann Pharmacother 33 (1999): 683-5

Some side effects of Fungizone For Tissue Culture may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide